2型糖尿病的个性化药物治疗
Personalized pharmacotherapy for Type 2 diabetes mellitus.
作者信息
Sathananthan Airani, Vella Adrian
出版信息
Per Med. 2009 Jul 1;6(4):417-422. doi: 10.2217/pme.09.3.
Abstract
Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.
摘要
全基因组连锁和关联研究已应用于2型糖尿病，以发现导致疾病风险的常见基因变异。虽然在理解基因变异如何导致糖尿病方面取得了进展，但对于遗传学如何改变药物反应的了解却较少。人们希望，未来药物遗传学能够帮助指导糖尿病的治疗，从而在一大批患者中提高控制效果，同时将副作用降至最低。
相似文献
1
Personalized pharmacotherapy for Type 2 diabetes mellitus.2型糖尿病的个性化药物治疗
Per Med. 2009 Jul 1;6(4):417-422. doi: 10.2217/pme.09.3.
2
Pharmacogenetics: potential role in the treatment of diabetes and obesity.药物遗传学：在糖尿病和肥胖症治疗中的潜在作用。
Expert Opin Pharmacother. 2008 May;9(7):1109-19. doi: 10.1517/14656566.9.7.1109.
3
Clinical translation of genetic predictors for type 2 diabetes.2型糖尿病遗传预测指标的临床转化
Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):100-6. doi: 10.1097/med.0b013e3283292354.
4
Genetics of type 2 diabetes and potential clinical implications.2 型糖尿病的遗传学及潜在临床意义。
Arch Pharm Res. 2013 Feb;36(2):167-77. doi: 10.1007/s12272-013-0021-x. Epub 2013 Feb 2.
5
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.全基因组关联分析鉴定了与 SUGAR-MGH 中二甲双胍和格列吡嗪急性反应相关的特定于祖先的遗传变异。
Diabetologia. 2023 Jul;66(7):1260-1272. doi: 10.1007/s00125-023-05922-7. Epub 2023 May 26.
6
Genetics of drug response in type 2 diabetes.2型糖尿病药物反应的遗传学
Curr Diab Rep. 2015 Jul;15(7):43. doi: 10.1007/s11892-015-0617-2.
7
Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes.糖尿病高血糖治疗中的药物遗传学及未来策略
Front Biosci (Landmark Ed). 2009 Jan 1;14(11):4348-62. doi: 10.2741/3532.
8
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.2 型糖尿病的药物遗传学：迈向个体化医学的途径。
Diabetes Metab Res Rev. 2019 Mar;35(3):e3109. doi: 10.1002/dmrr.3109. Epub 2019 Jan 7.
9
Personalized medicine: Genetic risk prediction of drug response.个性化医疗：药物反应的遗传风险预测。
Pharmacol Ther. 2017 Jul;175:75-90. doi: 10.1016/j.pharmthera.2017.02.036. Epub 2017 Feb 14.
10
Insights from genome-wide association studies of drug response.药物反应的全基因组关联研究的见解。
Annu Rev Pharmacol Toxicol. 2013;53:299-310. doi: 10.1146/annurev-pharmtox-011112-140237. Epub 2012 Oct 16.
引用本文的文献
1
An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus.2 型糖尿病药物治疗的分子和细胞基础的最新进展。
Int J Mol Sci. 2023 May 26;24(11):9328. doi: 10.3390/ijms24119328.
2
The methodology of glucose monitoring in type 2 diabetes mellitus.2型糖尿病患者血糖监测方法
Clujul Med. 2013;86(2):93-6. Epub 2013 May 9.
3
Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.胰高血糖素样肽 1 受体延长和间断刺激对胃排空和血糖的比较影响。
Diabetes. 2014 Feb;63(2):785-90. doi: 10.2337/db13-0893. Epub 2013 Oct 2.
4
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.2 型糖尿病的个体化治疗：药物遗传学数据的临床意义。
Mol Diagn Ther. 2012 Oct;16(5):285-302. doi: 10.1007/s40291-012-0002-7.
5
An NIH National Center for Advancing Translational Sciences: is a focus on drug discovery the best option?美国国立卫生研究院国家推进转化科学中心：专注于药物研发是最佳选择吗？
Nat Rev Drug Discov. 2011 Jun;10(6):471. doi: 10.1038/nrd3357-c1. Epub 2011 May 20.
6
Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.外源性胰高血糖素样肽-1 可减轻 2 型糖尿病危重症患者幽门后营养输注的血糖反应。
Crit Care. 2011;15(1):R35. doi: 10.1186/cc9983. Epub 2011 Jan 21.
本文引用的文献
1
Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.2型糖尿病全基因组关联扫描结果在糖尿病预防计划中的扩展。
Diabetes. 2008 Sep;57(9):2503-10. doi: 10.2337/db08-0284. Epub 2008 Jun 10.
2
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.胰高血糖素样肽受体激动剂和二肽基肽酶-4抑制剂治疗糖尿病：临床试验综述
Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414.
3
Effects of intensive glucose lowering in type 2 diabetes.强化降糖对2型糖尿病的影响。
N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.
4
Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy.2型糖尿病的遗传易感性及其对抗糖尿病治疗的意义。
Annu Rev Med. 2008;59:95-111. doi: 10.1146/annurev.med.59.090706.135315.
5
Prime suspect: the TCF7L2 gene and type 2 diabetes risk.首要嫌疑对象：TCF7L2基因与2型糖尿病风险。
J Clin Invest. 2007 Aug;117(8):2077-9. doi: 10.1172/JCI33077.
6
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.转录因子7样蛋白2（TCF7L2）基因多态性携带者中胰高血糖素样肽-1诱导的胰岛素分泌受损。
Diabetologia. 2007 Dec;50(12):2443-50. doi: 10.1007/s00125-007-0753-6. Epub 2007 Jul 28.
7
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.肠促胰岛素疗法治疗2型糖尿病的疗效与安全性：系统评价与荟萃分析
JAMA. 2007 Jul 11;298(2):194-206. doi: 10.1001/jama.298.2.194.
8
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.有机阳离子转运体1（OCT1）基因变异对二甲双胍作用的影响。
J Clin Invest. 2007 May;117(5):1422-31. doi: 10.1172/JCI30558.
9
Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.在2型糖尿病患者中，吡格列酮治疗反应与脂蛋白脂肪酶S447X变体相关。
Int J Clin Pract. 2007 Apr;61(4):552-7. doi: 10.1111/j.1742-1241.2006.01242.x.
10
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.二肽基肽酶-4抑制剂：临床数据及临床意义
Diabetes Care. 2007 Jun;30(6):1344-50. doi: 10.2337/dc07-0233. Epub 2007 Mar 2.
Zotero 插件